Expertise in
42
conditions

Dr. Jason R. Gotlib

Hematology
Stanford University
875 Blake Wilbur Dr, 
Palo Alto, CA 
Accepting New Patients
Offers Telehealth
Expertise in
42
conditions
Stanford University
875 Blake Wilbur Dr, 
Palo Alto, CA 

Overview

Jason Gotlib is a Hematologist practicing medicine in Palo Alto, California.

Dr. Gotlib is highly rated in 42 conditions, according to our data. His clinical expertise encompasses Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), Myelofibrosis, Bone Marrow Aspiration, and Tissue Biopsy.

He is actively involved in clinical research, co-authoring 252 peer reviewed articles and participating in 14 clinical trials. Dr. Gotlib is currently accepting new patients.

Specialties

Hematology

Licenses

Internal Medicine in CA

Hospital Affiliations

Stanford Health Care Tri-Valley
Community Hospital Of The Monterey Peninsula
Stanford Health Care

Languages Spoken

English

Gender

Male

Insurance

Accepted insurance can change. Please verify directly with the provider.

Find your insurance
Find your insuranceClose

Accepted insurance plans:

Aetna
  • EPO
  • HMO
  • POS
  • PPO
Alignment Health Plan
  • MEDICARE MAPD
  • MEDICARE SNP
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
Anthem BCBS
  • EPO
  • HMO
  • POS
  • PPO
Blue Shield of California
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE-MEDICAID PLAN
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Cigna
  • EPO
  • HMO
  • PPO
Health Care Services Corporation
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • OTHER COMMERCIAL
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
  • PPO
Humana
  • HMO
  • INDEMNITY
  • POS
  • PPO
Medicaid
  • OTHER MEDICAID
  • STATE MEDICAID
UnitedHealthcare
  • EPO
  • HMO
  • POS
  • PPO
Wellcare
  • EPO
  • HMO
  • INSURANCE PLAN
  • MANAGED MEDICAID PLAN
  • MEDICARE MAPD
  • MEDICARE PDP
  • MEDICARE SNP
  • MEDICARE-MEDICAID PLAN
  • OTHER MEDICARE
  • OTHER MEDICARE PART D
View 5 Less Insurance Carriers -

Locations

Stanford University
875 Blake Wilbur Dr, Palo Alto, CA 94304
Other Locations
Stanford Hospital and Clinics
300 Pasteur Dr, Stanford, CA 94305

Clinical Research

Clinical research consists of overseeing clinical studies of patients undergoing new treatments and therapies, and publishing articles in peer reviewed medical journals. Providers who actively participate in clinical research are generally at the forefront of the fields and aware of the most up-to-date advances in treatments for their patients.

13 Clinical Trials

Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
Phase 2 Study of Ruxolitinib in Idiopathic Hypereosinophilic Syndrome and Primary Eosinophilic Disorders
Enrollment Status: Active_not_recruiting
Publish Date: September 01, 2026
Intervention Type: Drug
Study Drug: Ruxolitinib
Study Phase: Phase 2
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
A Randomized Phase III Study of Ibrutinib Plus Obinutuzumab Versus Ibrutinib Plus Venetoclax and Obinutuzumab in Untreated Older Patients (>/= 65 Years of Age) With Chronic Lymphocytic Leukemia (CLL)
Enrollment Status: Active_not_recruiting
Publish Date: August 28, 2026
Intervention Type: Drug, Biological, Other
Study Drugs: Ibrutinib, Obinutuzumab, Venetoclax
Study Phase: Phase 3
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
An Open-label, Single Arm, Phase 2 Study to Evaluate Efficacy and Safety of Avapritinib (BLU-285), A Selective KIT Mutation-targeted Tyrosine Kinase Inhibitor, in Patients With Advanced Systemic Mastocytosis
Enrollment Status: Completed
Publish Date: April 24, 2026
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
A Phase 2, Open-Label, Monotherapy, Multicenter Study to Evaluate the Efficacy and Safety of Pemigatinib (INCB054828) in Subjects With Myeloid/Lymphoid Neoplasms With FGFR1 Rearrangement - (FIGHT-203)
Enrollment Status: Completed
Publish Date: November 18, 2025
Intervention Type: Drug
Study Phase: Phase 2
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
A 3-Part, Randomized, Double-Blind, Placebo-Controlled Phase 2 Study to Evaluate Safety and Efficacy of Avapritinib (BLU-285), a Selective KIT Mutation-Targeted Tyrosine Kinase Inhibitor, in Indolent and Smoldering Systemic Mastocytosis With Symptoms Inadequately Controlled With Standard Therapy
Enrollment Status: Active_not_recruiting
Publish Date: September 23, 2025
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 2
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Tagraxofusp (SL-401) in Patients With Chronic Myelomonocytic Leukemia (CMML)
Enrollment Status: Completed
Publish Date: January 06, 2025
Intervention Type: Drug
Study Drug: Tagraxofusp
Study Phase: Phase 1/Phase 2
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies
Enrollment Status: Completed
Publish Date: March 17, 2023
Intervention Type: Drug
Study Drug: Avapritinib
Study Phase: Phase 1
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Prospective Evaluation of Ruxolitinib Efficacy for CNL/aCML Patients With Mutation of CSF3R
Enrollment Status: Completed
Publish Date: November 16, 2020
Intervention Type: Other, Drug
Study Phase: Phase 2
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Randomized Trial of Pegylated Interferon Alfa-2a Versus Hydroxyurea Therapy in the Treatment of High Risk Polycythemia Vera (PV) and High Risk Essential Thrombocythemia (ET)
Enrollment Status: Completed
Publish Date: April 30, 2019
Intervention Type: Drug
Study Phase: Phase 3
A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
A Study of Brentuximab Vedotin (SGN-35) in CD30-Positive Systemic Mastocytosis With or Without an Associated Hematological Clonal Non-Mast Cell Lineage Disease (AHNMD)
Enrollment Status: Completed
Publish Date: January 29, 2019
Intervention Type: Drug
Study Phase: Phase 2
View 9 Less Clinical Trials

252 Total Publications

NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
NCCN Guidelines® Insights: Myeloproliferative Neoplasms, Version 2.2026.
Journal: Journal of the National Comprehensive Cancer Network : JNCCN
Published: July 09, 2026
Similar Doctors
Expertise in
36
conditions
Expertise in
36
conditions
Referral may be required

Stanford Hospital And Clinics

300 Pasteur Dr, 
Stanford, CA 
 (0.2 miles away)
650-723-0822
Languages Spoken:
English
See accepted insurances
Offers Telehealth

David Miklos is a Hematologist practicing medicine in Stanford, California. Dr. Miklos is highly rated in 36 conditions, according to our data. His clinical expertise encompasses Chronic Graft Versus Host Disease (cGvHD), B-Cell Lymphoma, Non-Hodgkin Lymphoma, Bone Marrow Transplant, and Bone Marrow Aspiration.

Expertise in
23
conditions
Expertise in
23
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (1.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Michaela Liedtke is a Hematologist practicing medicine in Palo Alto, California. Dr. Liedtke is highly rated in 23 conditions, according to our data. Her clinical expertise encompasses Primary Amyloidosis, Acute Lymphoblastic Leukemia (ALL), Multiple Myeloma, Bone Marrow Aspiration, and Bone Marrow Transplant.

Expertise in
13
conditions
Expertise in
13
conditions
Referral may be required

Stanford Hospital And Clinics

965 High St, 
Palo Alto, CA 
 (1.1 miles away)
650-723-4000
Languages Spoken:
English
See accepted insurances
Offers Telehealth

Tait Shanafelt is a Hematologist practicing medicine in Palo Alto, California. Dr. Shanafelt is highly rated in 13 conditions, according to our data. His clinical expertise encompasses Chronic Lymphocytic Leukemia (CLL), Chronic B-Cell Leukemia (CBCL), Leukemia, Bone Marrow Aspiration, and Bone Marrow Transplant.

Frequently Asked Questions about Dr. Jason R. Gotlib

How do I make an appointment with Dr. Jason R. Gotlib?

You can book an appointment with Dr. Jason R. Gotlib by calling their office at 650-498-6000. MediFind provides direct contact information so you can schedule visits, second opinions, or consultations without navigating third-party calendars.

Is Dr. Jason R. Gotlib a top-rated expert for Systemic Mastocytosis?

MediFind is an objective health platform that identifies experts based on real-world data. Dr. Jason R. Gotlib is classified as an Elite expert for Systemic Mastocytosis, meaning they are among the top experts in the country for this condition. This ranking is based on their volume of patients, published research, and peer connections.

What conditions does Dr. Jason R. Gotlib specialize in?

While Dr. Jason R. Gotlib is a Hematology, they have specific expertise in Systemic Mastocytosis, Mast Cell Activation Syndrome (MCAS), and Myelofibrosis. MediFind analyzes a doctor's articles and referral patterns to identify their specific areas of focus within Hematology.

Does Dr. Jason R. Gotlib participate in research or clinical trials?

Yes. Dr. Jason R. Gotlib has published 252 articles and abstracts on conditions like Systemic Mastocytosis. You can view a list of Dr. Jason R. Gotlib's latest peer-reviewed publications and clinical trial participation on their profile to see if they are active in new treatments.

Does Dr. Jason R. Gotlib accept my insurance?

Dr. Jason R. Gotlib accepts most major insurance plans, including Aetna and Alignment Health Plan. We recommend calling the office directly at 650-498-6000 to verify that your specific plan is currently accepted before your visit.

Areas of Expertise

MediFind evaluates expertise by pulling from factors such as number of articles a doctor has published in medical journals, participation in clinical trials, speaking at industry conferences, prescribing and referral patterns, and strength of connections with other experts in their field.

Learn more about MediFind’s expert tiers

Find Dr. Gotlib's expertise for a condition
ConditionClose
View All 9 Elite Conditions
View All 13 Distinguished Conditions
View All 20 Advanced Conditions
View All 38 Experienced Conditions
Want to save this doctor for later?
Sign Up
Is this your doctor?
Find A Second Opinion
Not sure about your diagnosis?
Check Your Symptoms
 
 
 
 
Learn about our expert tiers
Learn More
Are you the provider on this profile?
Claim Profile